Erythropoietin as candidate for supportive treatment of severe COVID-19.

Mol Med · 2020 · PMC7297268 · PMID 32546125

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This highly significant prediction of a worse outcome explains the twofold higher very early death rate in the EPO group (for more information, visit http://www.epo-study.de/index_eng.html ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.